Phase II studies have shown that lasofoxifene, a next-generation selective estrogen-receptor modulator, increased bone mineral density and improved both objective measures of vaginal atrophy and reported symptoms. Margery Gass, MD, and a team from the University of Cincinnati Medical Center reported yesterday that a double-blind, randomized, placebo-controlled Phase III trial produced similar results.
Phase II studies have shown that lasofoxifene, a next-generation selective estrogen-receptor modulator, increased bone mineral density and improved both objective measures of vaginal atrophy and reported symptoms. Margery Gass, MD, and a team from the University of Cincinnati Medical Center reported yesterday that a double-blind, randomized, placebo-controlled Phase III trial produced similar results.
A group of 445 postmenopausal women with symptomatic vaginal atrophy (VA) were randomly assigned to receive lasofoxifene (0.25 mg/day or 0.5 mg/day) or placebo. Clinical effect was assessed using vaginal pH and vaginal cytology to determine the maturation index (superficial, intermediate, and parabasal cells). At screening, women were required to have no more than 5% superficial cells and vaginal pH of more than 5.
The results were clear, Dr. Gass said. By week 12, there were adjusted mean decreases in parabasal cells of 38% for the lasofoxifene 0.25 group, 37% for the lasofoxifene 0.5 group, and 3% for the placebo group (P
Gass M, Kagan R, Simon J, Spino C, Barcomb L. Objective measures of vaginal atrophy are improved with lasofoxifene, a next-generation selective estrogen receptor modulator. Obstet Gynecol. 2005;105(4 suppl):71S.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More